Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
VCZrXqpDVZapMnb7